Blood Group A Glycolipid Antigen Expression in Kidney, Ureter, Kidney Artery, and Kidney Vein from a Blood Group A,Le(a-b+) Human Individual
|
|
- Everett Smith
- 5 years ago
- Views:
Transcription
1 THE JOURNAL OF BKXOGICAL CHEMISTRY &I 1990 by The American Society for Biochemistry and Molecular Biology, Inc. Vol. 265, No. 34, Issue of December 5, pp ,199O Printed in U.S.A. Blood Group A Glycolipid Antigen Expression in Kidney, Ureter, Kidney Artery, and Kidney Vein from a Blood Group A,Le(a-b+) Human Individual EVIDENCE FOR A NOVEL BLOOD GROUP A HEPTAGLYCOSYLCERAMIDE BASED ON A TYPE 3 CARBOHYDRATE CHAIN* (Received for publication, June 12, 1990) Jan HolgerssonSj, Henrik Clausenllll, Sen-itiroh Hakomori 11, Bo E. SamuelssonS, and Michael E. Breimer** From the SDepartment of Medical Biochemistry, University of Gdteborg, P. 0. Box 33031, S Goteborg, the **Department of Surgery, Sahlgren s Hospital, University of Gdteborg, S Gbteborg, Sweden, the IlRoyal Dental College, Copenhagen, Denmark, and 11 the Biomembrane Institute and University of Washington, Seattle, Washington Kidney, ureter, kidney artery, and kidney vein tissue were obtained from a single human transplant specimen. The donors erythrocyte blood group phenotype was AILe(a-b+). Total non-acid glycolipid fractions were isolated and individual glycolipid components were identified by immunostaining thin layer plates with a panel of monoclonal antibodies and by mass spectrometry of the permethylated and permethylatedreduced total glycolipid fractions. The dominating glycolipids in all tissues were mono- to tetraglycosylceramides. In the kidney, ureter, and artery tissue less than 1% of the glycolipids were of blood group type, having more than 4 sugar residues. In contrast, 14% of the vein glycolipids were of blood group type, and the dominating components were type 1 chain blood group H pentaglycosylceramides and A hexaglycosylceramides. Trace amounts of structurally different blood group A glycolipids (type 1 to 4 core saccharide chains ) with up to 10 sugar residues were found in the kidney, ureter, and vein tissues, including evidence for a novel blood group A heptaglycosylceramide based on the type 3 chain in the vein. The only detected A glycolipid antigen in the artery tissue was the blood group A difucosyl type 1 chain heptaglycosylceramide (ALeb) structure. Blood group Lewis and related antigens (Lea, Leb, and ALeb) were expressed in the kidney, ureter, and artery, but were completely lacking in the vein, indicating that the Le gene-coded al-4-fucosyltransferase was not expressed in this tissue. The X and Y antigens (type 2 chain isomers of the Le and Leb antigens) were detected only in the kidney tissue. In recent years a growing structural complexity of the blood group ABH and related carbohydrate antigens has been documented (1). Several new core saccharide structures carrying the antigenic determinants as well as structures indicating *This work was supported by Grants 6521 and 8452 from the Swedish Medical Research Council, Grant 3967 for the mass spectrometry service, and Grant P from the Swedish National Board for Technical Development. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked aduertisement in accordante with 18 U.S.C. Section 1734 solely to indicate this fact. Supported by the Gijteborg Medical Society, the Faculty of Medicine, Gdteborg, and the Prof. L.-E. Gelin Foundation. To whom correspondence should be addressed. interactions between blood group systems have been found. The expression of these antigens in human tissues is a result of the interaction of several gene systems such as the ABO, H, Se, Le, 1, and P blood group systems (l-3). In addition, also other, mostly unknown factors influence the expression of these antigens exemplified by the difference in antigen expression found in various organs within a single individual (4-6) and also between different cells in a certain organ (7, 8). An attempt has been made to correlate the tissue-specific expression of different blood group antigens to the embryological origin of the tissue (3). The type 1 chain ABH antigens are thought to be of endodermal origin, regulated by the Se and.le genes, while the type 2 chain antigens, independent of Se and Le genes, are thought to be of ectodermal and mesodermal origin (3). With some exceptions, earlier studies speak in favor of this theory (3). Human erythrocytes (9) and granulocytes (lo), being of mesodermal origin, have been shown to contain mainly type 2 chain compounds, whereas the blood group glycolipid antigens in human small intestine are dominated by type 1 chain compounds, which are exclusively present in the epithelial cells of the bowel (7). However, the increasing number of antigens identified have made the situation more complicated, exemplified by the kidney (11) and ureter (8) where the type 4 chain A antigen is the dominating blood group A glycolipid. The structural difference of the blood group carbohydrate antigens can be recognized by the immune system. This is illustrated by the production of monoclonal antibodies against structurally different blood group A antigens (type l-4 structures) (4, 12) and in the clinical situation were antibodies specific for a certain A antigen structure have been found in patients receiving ABO incompatible blood transfusions (13) or kidney transplants (14). In many of these ABO incompatible kidney transplantations, the graft was lost due to kidney artery or kidney vein thrombosis. Therefore, an extended knowledge about the structural polymorphism and the cell- and tissue-specific distribution of the ABH and related antigens within a kidney graft is needed. This paper describes the expression of the non-acid glycolipids in the kidney, ureter, artery, and vein tissues from a single human kidney specimen. The blood group glycolipids were structurally identified by a combination of thin layer chro- H. Brynger, M. E. Breimer, and B. E. Samuelsson, unpublished observation
2 Blood Group A Glycolipid Expression in Human Kidney, Ureter, Vein, and Artery TABLE I Antigen specificity of the mouse monoclonal antibodies used in the immunostaining experiments Antibody Fig. 1 Code no. Specificity Ref. Anti-A all types Plate B Dakopatts A581 Terminal A trisaccharide 19 Anti-A type 1 Plate C AH-21 A type 1, monofucosyl 20 Anti-A type 2 Plate D HH-4 A type 2, monofucosyl 12 Anti-A type 3 Plate E TH-1 Atype 21 Anti-A type 3 and 4 Plate F HH-5 Atype3and4 12 Anti-ALe Plate G HH-3 A type 1, difucosyl 22 Anti-Lea Plate H XALA Chembiomed Le terminal Anti-Leh Plate I 9ALB Chembiomed Leb/H type 1 terminal* Anti-X SH-1 X terminals* Anti-Y AH-6 Y terminals 20 Anti-AY HH-2 A type 2, difucosyl 22 Anti-AGA, MH-3 A on ganglioseries backbone This antibody was shown to cross-react with the blood group H active pentasaccharide based on a type 1 chain. b A. Singhal, S. Nance, S. Hakomori, unpublished observation. T. White, S. Hakomori, H. Clausen, unpublished observation. matography using a panel of specific monoclonal antibodies for detection and by mass spectrometry of the glycolipid mixtures. MATERIALS AND METHODS Tissue Specimens-The kidney tissue specimen discarded for lack of suitable recipient was obtained from the transplantation unit, Sahlgren s Hospital. The donors red blood cells were blood group typed as A,Le(a-b+). As the specimen was aimed for transplantation purposes it was perfused with kidney storage solution, kept cool and sterile. The ureter-pelvis, the artery, and the vein were dissected free from the kidney. Glycolipid Preparation-Total non-acid glycosphingolipid fractions were prepared as described (15) from the kidney, ureter, vein, and artery tissues. Thin Layer Chromatography-Thin layer chromatography was performed on high performance thin layer chromatography plates (Merck, Darmstadt, Federal Republic of Germany) and solvent was chloroform/methanol/water, 60:35:8 (v/v/v). Detection was accomplished by a chemical reagent, anisaldehyde (15), or by autoradiography after incubating the plate with monoclonal antibodies using a modification of the method by Magnani et al. (16, 17). For quantitative analysis of glycolipid components, the plates were sprayed with a copper acetate reagent (18) and scanned at 500 nm with a CS 930 thin layer chromatography scanner (Shimadzu, Japan). Signals were integrated and plotted on a Shimadzu DR-2 recorder using base-line correction for optimal calculations of peak areas. Peak areas were converted into absolute weights by using a standard curve prepared by serial dilutions of globotetraosylceramide. Monoclonal Antibodies-The mouse monoclonal antibodies used for immunostaining of the thin layer plates are listed in Table I. Reference Glycolipids-The blood group A active hexaglycosylceramides based on type 1 (A-6-l) and type 2 (A-6-2) carbohydrate chains were from human meconium (23) and human erythrocytes (12), respectively. The A active nonaglycosylceramide based on type 3 chain (A-9-3) was from human erythrocytes (21, 24) and the A active hexaglycosylceramide based on gangliotetraosylceramide (AGA,) was biosynthesized in uitro.3 The A active heptaglycosylceramide based on type 4 chain (A-7-4) was from human kidney (ll), the type 1 chain difucosyl A active heptaglycosylceramide (A-7-l) (5), the blood group Leh hexaglycosylceramide (Les-6) (5), and the Le The sugar types are abbreviated for mass spectrometry to Hex for hexose, HexNAc for N-acetylhexosamine and dhex for deoxyhexose. The ceramide types are abbreviated to n for non-hydroxy and h for hydroxy fatty acids, d for dihydroxy, and t for trihydroxy base. In the shorthand designation for blood group glycolipids, the letter(s) indicates blood group determinant, the first numeral, the number of sugar residues, and the second numeral, the type of carbohydrate chain. Thus, A-6-l means a hexaglycosylceramide with a blood group A determinant based on a type 1 carbohydrate chain. AGA, means a blood group A hexaglycosylceramide based on the gangliotetraosylceramide structure. T. White, S. Hakomori, and H. Clausen, unpublished observation. pentaglycosylceramide (Lea-5) (25) were from human small intestine. The blood group X pentaglycosylceramide (X-5), the Y hexaglycosylceramide (Y-6), and the type 2 chain difucosyl A active heptaglycosylceramide (A-7-Z) were from dog small intestine (26). Mass Spectrometry-The total non-acid glycolipid fractions were permethylated (27, 28) and reduced with LiAlH, (29) for mass spectrometry. All experiments were performed on a High Field ZAB 2F instrument equipped with an electron ionization source and a programmable source heater controller (VG Analytical, Manchester). The mass spectrometer is connected to a VG Analytical 11/250 computer system, based on the PDP11/24 with a 500 kilobytes memory and a 96 MB disc system. The samples were analyzed as permethylated and permethylated-reduced derivatives using the in beam technique (30). Glycolipids with increasing sugar chain length are distilled off as the temperature in the ion source rises (31, 32), and spectra are recorded continuously. About 10 erg of the permethylated samples were evaporated by a temperature rise of 6 C/min starting at 200 C. Spectra (m/t ) were collected every 30 s. The permethylated-reduced samples were analyzed under two slightly different conditions. First, 10 pg of sample (20 fig for the artery) were used and spectra (m/r ) were collected every 30 s starting at 200 C followed by a temperature rise of 6 C/min. Second, about 40 rg of sample for the kidney and ureter and about 60 Fg for the vein and artery were analyzed. Spectra (m/z ) were recorded every 30 s with a temperature rise of 6 C/min starting at 270 C. All temperature gradients were stopped at 360 C. The accelerating voltage was 7 kv when a scan range up to m/z 3000 was used, otherwise the accelerating voltage was 8 kv. Trap current was 500 PA and electron energy was 40 ev. For interpretation of mass spectra see (30-32). RESULTS Total amount of non-acid glycolipids isolated from the kidney was 78.6 mg, ureter 1.3 mg, vein 2.5 mg, and artery 0.3 mg, corresponding to 3.6, 2.5, 5.4, and 0.7 mg/g dry tissue weight, respectively. Fig. 1A shows the thin layer chromatogram of the total non-acid glycolipid fractions. All bands seen on the plate, except for these marked +, were colored green with the anisaldehyde reagent and thus contained carbohydrate (15). The kidney tissue (Fig. la, lane 1 and Table II) contain mono- to tetraglycosylceramides as major components and small amounts of a pentaglycosylceramide. The chemical structures of these compounds have been reported before (7, 33-35) as glucosylceramide, galactosylceramide, lactosylceramide, digalactosylceramide, globotriaosylceramide, globotetraosylceramide together with a mixture of GalPI- 3globotetraosylceramide (IV GalGb&er) and the blood group X pentaglycosylceramide (1II FucnLcCer). No bands migrating below the five-sugar region are seen by chemical staining. The ureter (Fig. la, lane 2 and Table II) contain mono- and diglycosylceramides as major components, small amounts of tri- and tetraglycosylceramides and trace amounts of com-
3 20792 Blood Group A Glycolipid Expression in Human Kidney, pounds migrating in the five- to seven-sugar region. This glycolipid pattern is similar to the pattern obtained from the analysis of epithelial cells and non-epithelial residue of a ureter from another tissue donor with the same blood group (8). The kidney vein and artery (Fig. la, lanes 3 and 4 and B A,l.A *I, types A581 - C 2 An,,-* type 1 AH Anti-A type 2 D H-d Anti-A type 3 -. TH-I E. UP-4,234 AN-A type 3 and 4 Anti-ALeb,234 Anti-Lea Anti-Leb/H type 1 FIG. 1. Thin layer chromatograms of total non-acid glycolipid fractions isolated from the kidney (lane I), ureter (lane 2), kidney vein (lane 3), and kidney artery (lane 4) of a blood group AILe(a-b+) human individual. Plate A was developed with a chemical reagent and plates B-I are autoradiograms after immunostaining the plate with monoclonal anti-a antibodies as defined in Table I. Appropriate reference glycolipids were applied to the right on each chromatogram as indicated. Note the lack of all A antigens except the ALe structure in the artery tissue and the complete absence of Lewis antigens in the vein tissue. Bands marked with + are non-glycolipid contaminants. Arrows indicate the sample origin. TABLE II Major glycolipid structure identified in kidney, ureter, kidney vein, and kidney artery obtained from a blood group A,Le(a-b+) human individual as based on thin layer chromatography, mass spectrometry, and antibody binding For abbreviations and shorthand designations see Footnote 2. The total amount of glycolipids and the relative composition of each component were established by densitometric scanning of the thin layer plate. Note that several minor glycolipid components (less than l%), which are listed in Table III, were detected by mass spectrometry and antibody binding. Glycolipid structure Hex-Cer Hex-Hex-Cer Hex-Hex-Hex-Cer HexNAc-Hex-Hex-Hex-Cer Hex-HexNAc-Hex-Hex-Hex-Cer Galbl-4(Fucol-3)GlcNAcHex-Hex-Cer Fucnl-2Gal@l-3GlcNAcHex-Hex-Cer GalNAccul-3(Fuccul-2)GalB1-HexNAc-Hex-Hex-Cer as mg/g dry tissue weight. amount expressed as percentage. (17)* (18) (26) (38) (51) (13) (12) (24) Vein (22) (5) (36) (23) Artery (19) (4) (32) (45) 0.7 (100) 0.05 (1) 0.44 (8) 0.33 (6) 3.6 Expressed h Relative Ureter Kidney (100) 2.5 (100) 5.4 (100) Table II) contain mono-, tri-, and tetraglycosylceramides and only small amounts of diglycosylceramides. The vein contains also compounds migrating as penta- and hexaglycosylceramides, while the artery tissue lacks these compounds. In addition to the glycolipids identified by the chemical reagent, several minor compounds were identified by mass spectrometry and antibody binding analysis, and the results are described below and summerized in Table III. Mass Spectrometry-Mass spectrometric analysis of the total non-acid glycolipid fractions isolated from the kidney, ureter, kidney artery, and vein tissues revealed the presence of both carbohydrate sequence and molecular ions for HexCer, Hex-Hex-Cer, Hex-Hex-Hex-Cer, and HexNAc-HexHex-Hex-Cer structures in all tissues (Table II). For the more complex glycolipids having more than 4 sugar residues a large variation in the expression of glycolipid species between the different tissues was found. The following presentation will be focused in detail on the blood group type glycolipids from the vein and data from the kidney, ureter, and artery tissue will be shortly described. Fig. 2 shows selected reconstructed mass chromatograms from the analysis of the permethylated-reduced total nonacid glycosphingolipid mixture of the kidney vein and the mass spectrum recorded at scan number 25 is reproduced in Fig. 3. The curves reproduced in Fig. 2 are the intense immonium ions from the 24:0 fatty acid species of each glycolipid. The carbohydrate sequence shown in the simplified formulae are based on sequence ion information obtained from the analysis of both the permethylated (Fig. 4) and permethylated-reduced (Fig. 3) derivatives. A partial separation of individual glycolipid components, according to molecular size, is obtained by rising the ion source temperature as shown in Fig. 2. The major glycolipid species in the vein are mono- (m/z 659), tri- (m/z 1037), tetra- (m/z 1268), and pentaglycosylceramides (m/z 1472) together with small amounts of di- (m/z 863) and hexaglycosylceramides (m/z 1703) and trace amounts of hepta- (m/z 1847), octa- (m/z 2081), and nonaglycosylceramides (m/z 2313). This is in accordance with the thin layer chromatography data (Fig. la, lane 3 and Table II). The major blood group glycolipid is a blood group H pentaglycosylceramide. The number of sugars (3 hexoses, 1 deoxyhexose, and 1 hexosamine) and fatty acid composition (16:0, 20:0, 22:0, 23~0, and 24:0 hydroxy fatty acids) is shown by the intense series of peaks at m/z 1360, 1416, 1444, 1458, and 1472 in Fig. 3. The peak at m/z 1404 formed by a loss of the fatty acid instead of the long chain... 1 Ureter, Vein, and Artery
4 Blood Group A Glycolipid Expression in Human Kidney, Ureter, Vein, and Artery TABLE Blood group type glycosphingolipids of kidney, ureter, kidney vein, and kidney artery from a single human blood group A,Le(a-b+) human individual The structures were tentatively assigned by a combination of thin layer mobility, immunostaining with monoclonal antibodies, and by mass spectrometry. GalNAcal-3(Fucotl-2)Gal-Hex-Cer Hex-HexNAc-Hex-Hex-Hex-Cer GalBl-4(Fucotl-3)GlcNAcHex-Hex-Cer Fucal-2Galpl-3GlcNAcHex-Hex-Cer Galal-3(Fucal-4)GlcNAcHex-Hex-Cer Tentative structure III Shorthand designation Kidney Ureter Vein Artery A-4 (-Y c+, - + (T) - - x H-5-l - c+, + (+) Lea (+) Fucocl-2Gal@l-3(Pucal-4)GlcNAc-Hex-Hex-Cer Leh-6 + C-1 + Fucal-2Galpl-4(Fucol-3)GlcNAcHex-Hex-Cerb Y-6 (3, Fucal-2Galpl-3GalNAc-Hex-Hex-Hex-Cer H GalNAccul-3(Fuccul-2)Gal@l-3GlcNAc-Hex-Hex-Cer A-6-l (I, GalNAccul-3(Fucal-2)Galbl-4GlcNAc-Hex-Hex-Cer* A GalNAcLul-3(Fuccul-2)Galpl-3GalNAcu-(dHex-)Hex-Hex-Cer A c=, - GalNAcal-3(Fuccul-2)Galpl-3(Fuccul-4)GlcNAc-Hex-Hex-Cer A-7-l GalNAcal-3(Fuccul-2)Galpl-4(Fucoll-3)GlcNAc-Hex-Hex-Cerb A GalNAcal-3(Fuccul-2)Galfi1-3GalNAc-Hex-Hex-Hex-Cer A dHex,2HexNAc,4Hex,Cer ldhex.3hexnac.4hex.cer 2dHex;3HexNAc;4Hex;Cer ldhex,4hexnac,5hex,cer 2dHex.4HexNAc.5Hex.Cer A-9 + (+) (+I A-10 A-11 + indicates the presence and - the absence of each compound. No quantification of the relative amount is given. The parentheses indicate that the presence or absence of this compound is not established with certainty. b Presence or lack of these compounds are based on the antibody staining experiments. base is evidence for an 01 position of the fatty acid hydroxyl group and also for tl&o, as the major long chain base. The ions at m/z 1119 in Fig. 4 originate from the whole saccharide chain plus part of the ceramide and the peak at m/z 1544 originates from a cleavage between the two hydroxy groups of the trihydroxy long chain base of the hydroxy 24:0 fatty acid species. Molecular ions (M-l) are seen at m/z 1756 in Fig. 3 and at m/z 1610 to 1784 in Fig. 4. Primary carbohydrate sequence ions are found in Fig. 3 at m/z 157 (189-32), 189, 624,640,828 and in Fig. 4 at m/z 157 (189-32), 189,361 (393-32), 393, 606 (638-32), 638, and 842. The carbohydrate sequence is further supported by the series of ions at m/z originating from the three inner sugars and the whole ceramide (Fig. 4) and by the peaks at m/z 892 to 1004 in Fig. 3, which consist of the ceramide, the 2 inner hexoses, and part of the hexosamine (5). The ions at m/z also indicate a type 1 carbohydrate chain (5, 32) which is further supported by the absence of m/z 182 in the spectrum of the permethylated derivative (Fig. 4) (32). The second major blood group type glycolipid is a blood group A hexaglycosylceramide. The intense fatty acid immonium ions are seen at m/z , the ions formed by the loss of the fatty acid at m/z 1635 and the molecular ions are found at m/z (Fig. 3). Carbohydrate sequence ions are seen at m/z 189, 246, 262, 624, 640, and 855 in Fig. 3 and at m/z 189, 228 (260-32), 260, 606 (638-32), 638, 883, and 1087 in Fig. 4. The evidence for this structure is further strengthened by scan no. 27 of the permethylated derivative (not shown). In this spectrum m/z 1291 (1087 plus a hexose), 1364 (1363+1), a series of peaks at m/z (whole sugar chain plus h22:o to h24:o fatty acids), and molecular ions at m/z 2029 were clearly seen. In addition to these two major blood group glycolipids several minor components could be identified by the appearance of series of immonium ions containing the whole carbohydrate chain and the fatty acid for the permethylated-reduced derivatives. Carbohydrate sequence ion from these components are, however, difficult to identify except for certain fragments which do not coincide with the ions from the major compounds. Evidence for a hexaglycosylceramide (2 deoxyhexoses, 3 hexoses, and 1 hexosamine) was given by ions at m/z 1618 and 1646 (Fig. 2) for the hydroxy 2210 and 24:0 fatty acid species in the permethylated-reduced spectrum. Carbohydrate sequence ions indicating a Leb or Y determinant were found at m/z 780 (812-32), 812, and 1016 for the permethylated derivative. The presence of a difucosylheptaglycosylceramide is given by the ions at m/z 1819 and 1847 (Figs. 2 and 3) for the non-hydroxy 22:0 and 24:0 fatty acids, and the corresponding molecular ions are seen at m/z 2104 and 2132 (Fig. 3). The carbohydrate sequence ion at m/z 1262 and the peak at m/z 1539 (1538+1) (not shown), corresponding to the whole sugar chain plus part of the ceramide, together with the absence of the sequence ions at m/z 1026 ( ) and 1058 in the spectrum of the permethylated derivative, indicate a HexNAc-(dHex-)Hex-HexNAc-(dHex-)Hex-Hex- Cer structure as shown in Fig. 2 and not a HexNAc-(dHex-) Hex-(dHex-)HexNAc-Hex-Hex-Cer structure. The presence of this structure was further strengthened by the reactivity in the six-sugar region with the THl antibody and the absence of reactivity with the antibodies (HH3 and HH2, respectively) specific for the ALeb and AY structures (see below). In the high mass region, two series of peaks were found indicating the presence of an oktaglycosylceramide (2 deoxyhexoses, 4 hexoses, and 2 hexosamines) and a nonaglycosylceramide (2 deoxyhexoses, 4 hexoses, and 3 hexosamines) as shown by the immonium ion curves at m/z 2081 and 2313, respectively, in Fig. 2. No conclusive sequence ions were identified for these structures. In a second analysis of the permethylated-reduced derivative, a larger amount of sample was analyzed and the magnet was scanned to cover only the high mass region (see Materials and Methods ). A lo-sugar component (1 deoxyhexose, 5 hexoses, and 4 hexasamines) was identified with immonium ions containing the whole sugar chains and the fatty acid present at m/z for the non-hydroxy 16:0 to hydroxy 20:0 fatty acid species. No peaks were found indicating structures with 11 or more sugar residues. No specific fragments indicating the presence of globoseriesbased blood group H (H-6-4) or A (A-7-4) structures were
5 20794 Blood Group A Glycolipid Expression in Human Kidney, Ureter, Vein, and Artery Hex.HexJ h24:o! KS x5 H~xNAc-H~x-H~xNAc-H~~-~~~ I703j HerNAc-HFX-HexNAc-H:x-Hex 6s 40 I HexNAc-Hex.Hex-He. Hex-HexNAc-Hex-Hex dtel n 25 e 1268; 24:o! --&a dhex2,hexnac2.hex4 208lj h24:o i a Temp %I 200 FIG. 2. Selected reconstructed mass chromatograms of a permethylated-reduced total non-acid glycosphingolipid mixture from the kidney vein of a blood group AILe(a-b+) human individual. The curves reproduced correspond to the relative abundance of the fatty acid containing immonium ions (indicated in the formulae) as a function of evaporation temperature. All curves were normalized against the curve for monoglycosylceramide. Ten rg of sample was evaporated by a temperature rise of 6 C/min started at a temperature of 200 C at scan 7. Spectra (mass range ) were recorded every 30 s Temp found in the vein tissue. These structures are present in the Leb antibodies are shown in Fig. 1, chromatograms B-I. In kidney (7) and ureter (8) as shown in Table III. addition, anti-x, anti-y, anti-ay, and anti-aga, antibodies The glycolipid samples from the kidney, ureter, and kidney were used (not shown). The antigenic specificity of the antiartery were analyzed as permethylated and permethylated- bodies used is known in detail (Table I). A very complex reduced derivatives in a similar manner and the results are pattern of blood group A glycolipids was found, with the listed in Table III. kidney and ureter having a similar thin layer immunostaining Binding of Various Monoclonal Antibodies to Kidney, Ure- pattern, the vein being unique in its high expression of type ter, Vein, and Artery Glycolipids Separated on Thin Layer 3 chain A glycolipid antigens and the artery having the ALeb Plates-The immunostaining of the non-acid glycolipid frac- glycolipid as its only blood group A glycolipid (Fig. 1, B-G). tions with mouse monoclonal antibodies with different blood The six-sugar region of the kidney and ureter (lanes 1 and 2) group A antigenic specificity together with anti-lea and anti- reacted with the A type 1 and 2 chain antibodies, while this
6 Blood Group A Glycolipid Expression in Human Kidney, Ureter, Vein, and Artery [M-H]+= I CH 1.1 I 1404~ (C"zh I HCOMe 1 L-b--- CH, ~ Me Me 189 ~ : NMe ~4 IJ I dhex:o-her-o~hern.k~o-he+hex-0-ch2-ch! / CH-CH-C,,,, [M-H] + = S 3 (C z)z, 246; ~ HexNAc;O-H&O-HexNAe;O-Hex-0-Hex-O-CH-CH- 0 FIG. 3. Mass spectrum (scan 25 of iig--dh;f Fig. 2) of the permethylated-re- k duced mixture of glycolipids from L A 644 the kidney vein of a blood group AILe(a-b+) human individual. Simplified formulae and proposed fragmentation of the major components are Rel. ht. 157 shown x2 +x4 11 I,'F YOMe F 2 TMe -CH-CH-CC,,,, 260 4bo I m/z region of the vein (lane 3) contained at least three different structures reacting with the anti-a type 1 (C), the anti-a type 2 (D), the anti-a type 3 (E), and anti-a type 3 and 4 (F) antibodies. In the seven-sugar region a band corn&rating with the A-7-4 reference was stained with the anti-a type 3 and 4 antibody (F) in the kidney and ureter, while this component was absent in the vein and artery. Only a very weak staining was seen in this region with the anti-a type 3 antibody (E), which is known to cross-react weakly with A type 4 structures (21), indicating that this band contain the A type 4 compound. In addition, the type 2 chain A-specific antibody stained the ureter in the seven-sugar region (D, lane 2). The eight/ninesugar region of the vein was stained strongly by the anti-a type 3 (E) and anti-a type 3 and 4 (F) antibodies, and weakly with the anti-a type 1 (C) and anti-a type 2 (D) antibodies. The other tissues were not stained in the eight/nine-sugar regions except for the kidney, where a faint band with eight sugars reacting with the anti-a type 2 antibody (D, lane 1) and a faint band with nine sugars reacting with the anti-a type 3 and anti-a type 3 and 4 antibodies were present (E and F, lane I). The 10/12-sugar region stained in the vein with anti-a type 2 (D), anti-a type 3 (E), and anti-a type 3 and 4 (F) antibodies. Neither the anti-a difucosyl type 2 chain antibody (HH-2) nor the anti-agal antibody (MH3) showed any reactivity in the tissues analyzed (not shown). The anti-lea (H) and anti-leb (I) antibodies reacted with structures migrating as Le pentaglycosylceramides and Le hexaglycosylceramides, respectively, in the kidney, ureter, and weakly in the artery, while no staining of the vein glycolipids was seen. The strong staining of the anti-leb antibody in the
7 20796 Blood Group A Glycolipid Expression in Human Kidney, Ureter, Vein, and Artery [M-H]+= I S J (SW,, 1118; YoMe 1 co L-j I 638; 842 I 1046; TMe, d exto-hextothfxnarto-hexto-hex:olch~-ch -c, /1376 I 722 T jy 7 ~ 0 1 CH+CH-C,,H,, [M-H]+=2029 FIG. 4. Mass spectrometric analysis of the permethylated total nonacid glycolipid mixture from the kidney vein of a blood group A,Le(a-b+) human individual. Ten pg of sample was evaporated by a temperature rise of 6 C/min started at 200 C. Scan 24 recorded at an ion source temperature of 310 C is shown. Simplified formulae of the major glycolipid components are given in the figure. Ret. loo- ht. O : 883 / 1087 I 1291 I F y 0 / : 0 I II CHTCH-C,,H,, cm 189 d ex I --x '7 I I I --x30 -x l-200 Moo 1600 m/z five-sugar region of chromatogram I is due to a cross-reaction with the blood group H type 1 pentaglycosylceramide.4.5 The anti-aleb antibody reacted with a seven-sugar compound in the kidney, ureter, and artery migrating as the reference A-7-1 glycolipid (G), while no reaction was seen with the vein glycolipids. The anti-x antibody strongly stained a band migrating as a pentaglycosylceramide in the kidney, while the other tissues were negative (not shown). A similar staining pattern has been shown for another anti-x antibody (36). The anti-y antibody stained very weakly a component in the six-sugar 4 A. Ulfvin, unpublished observation. Blood group A glycolipid antigens based on the type 1 carbohydrate chain have the A trisaccharide terminally placed on a GalPI- 3GlcNAc@ sequence; the type 2 chain on a Galfll-4GlcNA@- sequence; the type 3 chain on a Gal@-3GalNAccu- sequence; and the type 4 chain on a Galpl-SGalNAcp- sequence. region in the kidney, while the other tissues were negative (not shown). The antibody binding data described above was compared with the results of the mass spectrometric analysis of the other tissues and the blood group glycosphingolipid structures tentatively assigned for the kidney, ureter, vein, and artery are summarized in Table III. DISCUSSION The present investigation has used a combination of mass spectrometry and immunostaining of thin layer chromatograms to provide evidence for partial structures of most of the non-acid glycosphingolipids in the kidney, ureter, renal vein, and artery tissue obtained from a single human individual. The analysis was performed on the total non-acid glycolipid mixtures isolated from each tissue. This was necessary due to the small amounts of glycolipids obtained, especially of blood
8 Blood Group A Glycolipid Expression in Human Kidney, Ureter, Vein, and Artery group type, which made it impossible to purify each component for structural studies. For example, the vein tissue contained 0.7 mg of total glycolipids of which about 14 percent (0.1 mg) were of blood group type and consisted of at least six different molecular species. Due to the individual specific distribution of the blood group type glycolipids (4-6), it is not possible to collect tissue from several individuals in order to increase the amount of each glycolipid. The analytical methods used established the structures of a large number of glycolipid structures present in the tissues. However, there are difficulties in the structural interpretation which can be exemplified by, for example, the four-sugar compound stained by the anti-a antibody reacting with all A determinants (Fig. 1 B, lane 3) and the compound strongly stained by the anti-a type 3 antibody migrating in the six-sugar region (Fig. le, lane 3) in the vein tissue. The four-sugar compound may be a blood group A tetraglycosylceramide based on the lactosyl core, previously identified in rat small (37) and large (38) intestine. This compound has not been found in human tissues before although its precursor, the H triglycosylceramide, has been found in human small intestinal epithelial cells (7). In the mass spectrometric analysis, fragments originating from such a blood group A tetraglycosylceramide all coincide with either the ions from the more abundant blood group A hexaglycosylceramide or globotetraosylceramide. Therefore, no unambiguous structural information concerning this compound is obtained. However, the use of the newly developed four sector instruments, where mass spectrometrymass spectrometry analysis is performed (39), may overcome this problem in mixture analysis (40). The only carbohydrate sequence having six sugars and a terminal A trisaccharide identified by mass spectrometry was HexNAc-(dHex-)Hex- HexNAc-Hex-Hex-Cer which originates from the type 1 and 2 chain A hexaglycosylceramides. However, these structures do not bind the TH-1 antibody. The binding could be explained by a seven-sugar repetitive A determinant based on lactosylceramide as suggested by the known binding epitope of the TH-1 antibody (21), GalNAcal-3(Fuccul-2)Gal/31- SGalNAccu-R. The ions seen at m/z 1819 and 1847 in the permethylated-reduced spectrum (Fig. 3) could derive from such a structure, but could also originate in the ALeb and AY structures. However, the absence in the permethylated spectrum of the sequence ions at m/z 1058 and 1026 (10X&-32), which are specific for the HexNAc-(dHex-)Hex-(dHex-)- HexNAc-terminal (41), together with the lack of reactivity with the anti-aleb and anti-ay antibodies exclude these structures as candidates for explaining the ions at m/z 1819 and 1847 (Fig. 3). Despite such problems in the interpretation of the results obtained by the mass spectrometric and thin layer chromatographic analysis, no other analytical methods are available at present to analyze glycolipid samples obtained in small amounts from unique and small tissue specimens. The dominating glycolipids present in all tissues were mono- to tetraglycosylceramides except for the vein and artery which only contained small amounts of diglycosylceramides (Table II). The mono- and diglycosylceramides present in the ureter consist of mainly one slow-moving band (Fig. la, lane 2) which is due to a unique ceramide composition of t18:o and t20:o bases in combination with hydroxy 22:0 and 24:0 fatty acids (mass spectrometric data not shown and Ref. 8). These molecular species originate from the epithelial cells of the ureter while the non-epithelial glycolipids contained d18:l base and non-hydroxy 16:0 to 24:0 fatty acids (8). The triand tetraglycosylceramides of the ureter have a less hydroxylated ceramide, and these components are present in the non-epithelial part of the tissue. The high degree of ceramide hydroxylation in epithelial tissues like the transitional epithelium of the urinary tract (8) and the epithelial cells of the small intestine (7) has been suggested to be due to the high physicochemical demands to which these cell membranes are exposed. The hydroxylated ceramide type has been suggested to stabilize the membrane and decrease its water permeability by forming lateral hydrogen bonds (42, 43). A large difference in the expression of the blood group type glycolipids in the different tissues was found. The kidney vein contained large amounts of type 1 chain-based H penta- and A hexaglycosylceramides and small amounts of several additional blood group A compounds based on type 1, 2, and 3 core saccharides. The vein, however, was unique in its high expression of both short- and long-chain blood group A glycolipid antigens, and especially in its relatively high content of type 3 chain-based antigens (Fig. 1 E, lane 3). A prerequisite for expression of the latter chain type is an active /31-3galactosyltransferase adding a galactose residue to the terminal N-acetylgalactosamine of the A trisaccharide (44). The expression of blood group antigens in the kidney and ureter was very similar to each other, having type 1 and 4 chain structures as the dominating species (8,ll). The kidney artery contained trace amounts of the ALeb heptaglycosylceramide but lacked completely the monofucosyl type 1 and type 2, the type 3, and the type 4 chain A structures. The arterial endothelium especially is known to be very sensitive to ischemia, j which might explain the low abundance of blood group type glycolipids in the artery. However, the presence of the ALeb compound contradicts this explanation. For the Lewis antigens another expression pattern was found. The Le pentaand Leb hexaglycosylceramides together with the ALeb heptaglycosylceramide were present in the kidney, ureter, and in small amounts in the artery, while the vein completely lacked these antigens. This indicates that the Le gene coded fucosyltransferase is not expressed in the vein. Further support for this is the accumulation in the vein of the H-5-l and A-6-l glycolipids, which are the precursors for the Le gene enzyme forming the Leb-6 and A-7-l glycolipids, respectively. The reason for, and the regulation of, this tissue-specific expression of blood group glycolipids is not known. However, it has been suggested that the glycosyltransferase expression is regulated at the level of transcription. In support of this suggestion is the finding that the level of Galcu2,6-sialyltransferase mrna varies up to loo-fold in different rat tissues, corresponding to the activity of the enzyme (45). Also Galot2,6-sialyltransferase mrna of varying sizes have been found in different rat tissues, which in part has been explained by an alternative splicing from a common gene sequence (46). Immunohistochemical studies of the expression of blood group antigens in human kidneys have shown that the ABH antigens present in the endothelial cells of the blood vessels were expressed independent of the secretor status of the individuals, while the ABH antigens in the distal tubulus and collecting ducts were only present in secretor individuals (47-49). The blood group Le and Leb antigens were only present in the distal and collecting tubules and were absent in the blood vessels (48, 49). As expected Leb antigens are absent in non-secretor individuals (49). According to Oriol and coworkers (3), mesodermal-derived tissues have ABH antigens with type 2 chain, which are independent of the Se and Le genes, while ABH antigens derived from tissues of endodermal origin have type 1 chain core and are synthesized by the Se and Le gene-derived enzymes. In the kidney, the vessels are of mesodermal origin and the collecting tubules of endodermal origin. The A type 1 chain antigens and the Lewis antigens R. Oriol and J. Wallwork, personal communication.
9 I, Blood Group A Glycolipid Expression in Human Kidney, Ureter, Vein, and Artery may therefore be located in the collecting tubules as well as the A type 4 structure, for which the expression in different kidneys are Se gene-dependent (19). In the ureter, the ABH antigens are located in the transitional epithelium and blood vessels (50), but the secretor status of the donors was not established in this study (50). From the degree of hydroxylation of the ceramide part (trihydroxy base-hydroxy fatty acid) of the blood group A-6-l and A-7-4 glycolipids present in the ureter, it can be assumed that these compounds are located in the epithelial cells of the ureter (8). Acknowledgments-Drs. G. Larson, K.-A. Karlsson, and N. Stromberg are acknowledged for the gift of reference compounds and Dr. P. Falk for the densitometrv analvsis. Special thanks to C. Nvbera for skilled technical assistance and W. Pimlott for mass spectrometri analysis (1990) Transplantation 49, Karlsson. K.-A. (1987) Methods Enzvmol Magnani; J. L., Smith, D. F., and Ginsburg; V. (1981) Anal REFERENCES 1. Clausen, H., and Hakomori, S. (1989) VOX Sung. 56, l Watkins, W. M. (1980) Ado. Hum. Genet. 10, l Oriol, R., LePendu, J., and Mollicone, R. (1986) VOX Sang. 51, Le Pendu, J., Lambert, F., Samuelsson, B. E., Breimer, M. E., Seitz, R. C.. Urdaniz. M. P.. Suesa. N.. Ratcliffe. M.. Francoise. A., Poschmann, A., Vifias, J., and Orio1, R. (1986) &coconju: gate J. 3, Breimer, M. E. (1984) AFC~. Biochem. Biophys. 228, Ulfvin, A., Breimer, M. E., Holgersson, J., Viiias, J., and Samuelsson, B. E. (1988) in Monoclonal Antibodies against Human Red Blood Cell and Related Antigens (Rouger. P., and Salmon, C., eds) pp , Libraire Arnette, Pa& 7. Biork. S.. Breimer. M. E.. Hansson. G. C.. Karlsson. K.-A.. and Leffler; H. (1987) J. Bidl. Chem. i62, Breimer, M. E., Hansson, G. C., and Leffler, H. (1985) J. Biochem. 98, Hakomori, S., and Young, W. W. (1983) in Sphingolipid Biochemistry (Kanfer, J. N.,-and Hakomori, S:, eds) pp , Plenum Publishing Corp., New York 10. Fukuda, M. N., Del< A., bates, J. E., Wu, P., Klock, J. C., and Fukuda, M. (1985) J. Biol. Chem. 260, Breimer, M. E., and Jovall, P.-A. (1985) FEBS Lett.179, Clausen, H., Levery, S. B., Nudelman, E., Baldwin, M., and Hakomori, S. (1986) Biochemistry 25, Rydberg, L., Breimer, M. E.,and Samuelsson, B. E. (1988) Trunsfusion 28, Biochem. 109, Hansson, G. C., Karlsson, K.-A., Larson, G., McKibbin, J. M., 46. Blaszczyk, M., Herlyn, M., Steplewski, Z., and Koprowski, H. (1983) J. Biol. Chem Fewster, M. E., Burns, B. J.; and Mead, J. F. (1969) J. Chromatogr. 43, Breimer, M. E., and Samuelsson, B. E. (1986) Transplantation 42, Abe, K., Levery, S. B., and Hakomori, 132, S. (1984) J. Zmmunol. Clausen, H., Levery, S. B., Nudelman, E., Tsuchiya, S., and 50. Hakomori, S. (1985) Proc. Nutl. Acud. Sci. U. S. A. 82, Clausen, H., McKibbin. J. M., and Hakomori. S. (1985) Biochemistry i4, Karlsson. K.-A.. and Larson. G. (1981) FEBS Z&t Breimer, M. E., Karlsson, HI, Karlsson, K.-A., Nilsson, K., Samuelsson, B. E., and Stromberg, N. (1988) Curbohydr. Res. 176, Smith, E. L., McKibbin, J. M., Karlsson, K.-A., Pascher, I., Samuelsson, B. E., Li, Y.-T., and Li, S.-C. (1975) J. Biol. Chem. 250, McKibbin, J. M., Spencer, W. A., Smith, E. L., Mansson, J.-E., Karlsson, K.-A., Samuelsson, B. E., Li, Y.-T., and Li, S.-C. (1982) J. Biol. Chem. 257, Ciucanu, I., and Kerek, F. (1984) Curbohydr. Res. 138, Larson, G.. Karlsson. H.. Hansson. G. C.., and Pimlott. W. (1987) Curbohydr. Res. 161, Karlsson, K.-A. (1974) Biochemistry 13, Breimer, M. E., Hansson, G. C., Karlsson, K.-A., Larson, G., Leffler, H., Pascher, I., Pimlott, W., and Samuelsson, B. E. (1980) in Advances in Muss Spectrometry (Quayle, A., ed) Vol. 8, pp , Hevden & Son Ltd., London, United Kingdom 31. Samuelsson, B. E. (1986) in Adoandes in Muss Specfrometry (1985) (Todd, J. F. J., ed) Vol. 10, pp , John Wiley & Sons Ltd., Chichester, United Kingdom 32. Breimer, M. E., Hansson, G. C., Karlsson, K.-A., Leffler, H., Pimlott, W., and Samuelsson, B. E. (1979) Biomed. Muss Spectrom. 6, Mirtensson. E. (1969) in Propress in the Chemistrv of Fats and other Lipids (Holman, R. T., ed) Vol. X, pp , Pergamon Press, Oxford 34. Makita, A. (1964) J. Biochem. (Tokyo) 55, Breimer, M. E., and Karlsson, Actu 755, K.-A. (1983) Biochim. Biophys. 36. Breimer, M. E., Hansson, G. C., and Larson, G. (1983) in Glycoconjugates (Chester, A., Heinegird, D., Lundblad, A., and Svensson, S., eds) pp , Rahm Publishing Co., Lund 37. Breimer, Ml E., Han&on, G. C., Karlsson, K.-A., and Leffler, H. (1982) J. Biol. Chem Hansson, G. C., Karlsson, K.-A., and Thurin, J. (1984) Biochim. Biophys. Actu Domon, B., and Costello, C. E. (1988) Biochemistry 27, Holgersson, J., Pimlott, W., Samuelsson, B. E., and Breimer, M. E. (1989) Rapid Commun. Muss Spectrom. 3, Smith, E. L., McKibbin, J. M., Breimer, M. E., Karlsson, K.-A., Pascher, I., and Samuelsson, B. E. (1975) Biochim. Biophys. Actu Pascher, I. (1976) Biochim. Biophys. Acta 455, Karlsson. K.-A. (1982) in Biological Membrane (Chapman. D.. ed) Vol. 4, pp. i-74, Academic-Press Inc., New York- Rvdberg, L., Breimer, M. E., Brynger, H., and Samuelsson, B. E. 44. Clausen, H., Levery, S. B., Nudelman, E. D., Stroud, M., Salyan, 45. M. E. K., and Hakomori, S. (1987) J. Biol. Chem. 262, Paulson, J. C., Weinstein, J., and Schauer, A. (1989) J. Biol. Chem. 264, O Hanlon, T. P., Lau, K. M., Wang, X., and Lau, J. T. Y. (1989) J. Biol. Chem. 264, BariCty, J., Oriol, R., Hinglais, N., Zanetti, M., Bretton, R., Dalix, A.-M., and Mandet, C. (1980) Kidney Znt. 17, Rouger, P., and Salmon, C. (1982) Blood Transfusion Zmmunohemutologv Cordon-Cardo, C., Lloyd, K. O., Finstad, C. L., McGroarty, M. E., Reuter, V. E., Bander, N. H., Old, L. J., and Melamed, M. R. (1986) Lab. Znuest. 55, Seal. G. M.. Rowland. R. G.. Thornalla. J. V.. Rudolph, Pfaff, D. S., Kamer, M., and Eble, J. N. (1985) J. Grol. R. A., 133,
10 Blood group A glycolipid antigen expression in kidney, ureter, kidney artery, and kidney vein from a blood group A1Le(a-b+) human individual. Evidence for a novel blood group A heptaglycosylceramide based on a type 3 carbohydrate chain. J Holgersson, H Clausen, S Hakomori, B E Samuelsson and M E Breimer J. Biol. Chem. 1990, 265: Access the most updated version of this article at Alerts: When this article is cited When a correction for this article is posted Click here to choose from all of JBC's alerts This article cites 0 references, 0 of which can be accessed free at
Distribution of molecular species of sphingomyelins in different parts of bovine digestive tract
Distribution of molecular species of sphingomyelins in different parts of bovine digestive tract M. E. Breimer Membrane Biochemistry Group, Department of Medical Biochemistry, University of Giiteborg,
More informationErythrocyte and Porcine Intestinal Glycosphingolipids Recognized by F4 Fimbriae of Enterotoxigenic Escherichia coli
Erythrocyte and Porcine Intestinal Glycosphingolipids Recognized by F4 Fimbriae of Enterotoxigenic Escherichia coli Annelies Coddens 1, Erik Valis 2, John Benktander 2, Jonas Ångström 2, Michael E. Breimer
More informationChemical characterization of neutral glycolipids in the human myeloid leukemias1
Chemical characterization of neutral glycolipids in the human myeloid leukemias1 John C. Klock, Jay L. D Angona, and Bruce A. Macher Cancer Research Institute and the Department of Medicine,* and Department
More informationCancer glycomics: identification of tumor-associated GlcNAc antigens
Supplementary Data 1 / 20 Cancer glycomics: identification of tumor-associated GlcNAc antigens SUPPLEMENTARY DATA Contents: 1. Structural analysis of cancer-associated glycosphingolipids.... 1 Methods...
More informationThe lactosylceramide binding specificity of Helicobacter pylori
Glycobiology vol. 8 no. 4 pp. 297 309, 1998 The lactosylceramide binding specificity of Helicobacter pylori Jonas Ångström 4, Susann Teneberg, Maan Abul Milh, Thomas Larsson, Iréne Leonardsson, Britt-Marie
More informationLactotetraosylceramide, a novel glycosphingolipid receptor for Helicobacter pylori, present in human gastric epithelium
Lactotetraosylceramide, a novel glycosphingolipid receptor for Helicobacter pylori, present in human gastric epithelium Teneberg, Susann; Leonardsson, Iréne; Karlsson, Hasse; Jovall, Per-Åke; Ångström,
More informationGlycosphingolipid composition of epithelial cells isolated along the villus axis of small intestine of a single human individual
Glycobiology vol. 22 no. 12 pp. 1721 1730, 2012 doi:10.1093/glycob/cws115 Advance Access publication on July 24, 2012 Glycosphingolipid composition of epithelial cells isolated along the villus axis of
More informationCharacterization of GM, ganglioside by direct inlet chemical ionization mass spectrometry
Characterization of GM, ganglioside by direct inlet chemical ionization mass spectrometry Toshio Ariga, Robert K. Yu, Mhoru S d, Susumu Ando, and Tadashi Miyatake Department of Biochemistry and Metabolism,
More informationHiroya Hidaka *1), Masaki Takiwaki 2), Mine Yamashita 2), Shinya Otsuki 1), Kenji Kawasaki 3), Mitsutoshi Sugano 3) and Takayuki Honda 4)
Mild acid hydrolysis of sphingolipids yields lysosphingolipids: a matrix-assisted laser desorption and ionization time-of-flight mass spectrometry study Hiroya Hidaka *1), Masaki Takiwaki 2), Mine Yamashita
More informationIdentification of carbohydrate structures that are possible
Proc. Natl. Acad. Sci. USA Vol. 85, pp. 4902-4906, July 1988 Microbiology Identification of carbohydrate structures that are possible receptors for Neisseria gonorrhoeae (bacterial bilding/glycolipids/lactose
More informationSupporting information
Supporting information Figure legends Supplementary Table 1. Specific product ions obtained from fragmentation of lithium adducts in the positive ion mode comparing the different positional isomers of
More informationStructural Elucidation of N-glycans Originating From Ovarian Cancer Cells Using High-Vacuum MALDI Mass Spectrometry
PO-CON1347E Structural Elucidation of N-glycans Originating From Ovarian Cancer Cells Using High-Vacuum MALDI Mass Spectrometry ASMS 2013 TP-708 Matthew S. F. Choo 1,3 ; Roberto Castangia 2 ; Matthew E.
More informationThe use of mass spectrometry in lipidomics. Outlines
The use of mass spectrometry in lipidomics Jeevan Prasain jprasain@uab.edu 6-2612 utlines Brief introduction to lipidomics Analytical methodology: MS/MS structure elucidation of phospholipids Phospholipid
More informationHelicobacter pylori binding non-acid glycosphingolipids in the human stomach
JBC Papers in Press. Published on September 19, 2018 as Manuscript RA118.004854 The latest version is at http://www.jbc.org/cgi/doi/10.1074/jbc.ra118.004854 Helicobacter pylori binding non-acid glycosphingolipids
More informationApplying a Novel Glycan Tagging Reagent, RapiFluor-MS, and an Integrated UPLC-FLR/QTof MS System for Low Abundant N-Glycan Analysis
Applying a Novel Glycan Tagging Reagent, RapiFluor-MS, and an Integrated UPLC-FLR/QTof MS System for Low Abundant N-Glycan Analysis Ying Qing Yu Waters Corporation, Milford, MA, USA APPLICATION BENEFITS
More informationThe structural basis of blood group A-related glycolipids in an A 3 red cell phenotype and a potential explanation to a serological phenomenon
Glycobiology vol. 21 no. 2 pp. 162 174, 2011 doi:10.1093/glycob/cwq143 Advance Access publication on October 6, 2010 The structural basis of blood group A-related glycolipids in an A 3 red cell phenotype
More informationPhospholipid characterization by a TQ-MS data based identification scheme
P-CN1716E Phospholipid characterization by a TQ-MS data based identification scheme ASMS 2017 MP-406 Tsuyoshi Nakanishi 1, Masaki Yamada 1, Ningombam Sanjib Meitei 2, 3 1 Shimadzu Corporation, Kyoto, Japan,
More informationOverview on the identification of different classes of. lipids by HPTLC (High Performance Thin Layer. Chromatography) and ITLC (Immuno Thin Layer
Overview on the identification of different classes of lipids by HPTLC (High Performance Thin Layer Chromatography) and ITLC (Immuno Thin Layer Chromatography) Iuliana Popa 1, Marie-Jeanne David 2, Daniel
More informationBarry Boyes 1,2, Shujuan Tao 2, and Ron Orlando 2
Barry Boyes 1,2, Shujuan Tao 2, and Ron Orlando 2 1 Advanced Materials Technology, Inc. Wilmington, DE USA 2 Complex Carbohydrate Research Center University of Georgia, Athens, GA USA bboyes@advanced-materials-tech.com
More informationSulfate Radical-Mediated Degradation of Sulfadiazine by CuFeO 2 Rhombohedral Crystal-Catalyzed Peroxymonosulfate: Synergistic Effects and Mechanisms
Supporting Information for Sulfate Radical-Mediated Degradation of Sulfadiazine by CuFeO 2 Rhombohedral Crystal-Catalyzed Peroxymonosulfate: Synergistic Effects and Mechanisms Submitted by Yong Feng, Deli
More informationDienes Derivatization MaxSpec Kit
Dienes Derivatization MaxSpec Kit Item No. 601510 www.caymanchem.com Customer Service 800.364.9897 Technical Support 888.526.5351 1180 E. Ellsworth Rd Ann Arbor, MI USA TABLE OF CONTENTS GENERAL INFORMATION
More informationAmmonia chemical ionization mass spectrometry of intact diacyl phosphatidylcholine
Ammonia chemical ionization mass spectrometry of intact diacyl phosphatidylcholine C. G. Crawford and R. D. Plattner Northern Regional Research Center, Agricultural Research Service, United States Department
More informationA new solvent system for the separation of neutral glycosphingolipids
A new solvent system for the separation of neutral glycosphingolipids K. Watanabe and Y. Arao Shigei Medical Research Institute, Division of Biochemistry, 2 1 17 Yamada, Okayama, 701-02, Japan Summary
More informationYuhua Liu, Noboru Fujitani, Yoshiro Koda, Mikiko Soejima, and Hiroshi Kimura
Volume 47(7): 889 894, 1999 The Journal of Histochemistry & Cytochemistry http://www.jhc.org ARTICLE Presence of H Type 3/4 Chains of ABO Histo-blood Group System in Serous Cells of Human Submandibular
More information774 [Vol. 39, *) The abbreviations used are: GIcNAc, N-acetylglucosamine; GalNAc, N-acetylgalactosamine;
774 [Vol. 39, 170. Separation and Identification of N-Acetylhexosamines and N Acetylneuraminic Acid by Two-dimensional Electrophoresis and Chromatography on Paper By Seiichi OHKUMA and Toshiaki SHINOHARA
More informationLecture 3. Tandem MS & Protein Sequencing
Lecture 3 Tandem MS & Protein Sequencing Nancy Allbritton, M.D., Ph.D. Department of Physiology & Biophysics 824-9137 (office) nlallbri@uci.edu Office- Rm D349 Medical Science D Bldg. Tandem MS Steps:
More informationLactotetraosylceramide, a Novel Glycosphingolipid Receptor for Helicobacter pylori, Present in Human Gastric Epithelium *
JBC Papers in Press. Published on March 25, 2002 as Manuscript M201113200 Lactotetraosylceramide, a Novel Glycosphingolipid Receptor for Helicobacter pylori, Present in Human Gastric Epithelium * Susann
More informationA new solvent system for the separation of neutral glycosphingolipids
A new solvent system for the separation of neutral glycosphingolipids K. Watanabe and Y. Arao Shigei Medical Research nstitute, Division of Biochemistry, 2 1 17 Yamada, Okayama, 71-2, Japan Summary A solvent
More informationRapid Lipid Profiling of Serum by Reverse Phase UPLC-Tandem Quadrupole MS
Rapid Lipid Profiling of Serum by Reverse Phase UPLC-Tandem Quadrupole MS Mark Ritchie and Evelyn Goh Waters Pacific Pte Ltd., Singapore A P P L I C AT ION B E N E F I T S Delivers a rapid 10-min MRM method
More information120. Paper Electrophoresis o f Hexosamines, N-Acetylhexosamines and N Acetylneuraminic Acid*l
534 [Vol. 39, 120. Paper Electrophoresis o f Hexosamines, N-Acetylhexosamines and N Acetylneuraminic Acid*l By Seiichi OHKUMA and Toshiaki SHINOHARA Biochemical Laboratory, Scientific Police Research Institute,
More informationNeosolaniol. [Methods listed in the Feed Analysis Standards]
Neosolaniol [Methods listed in the Feed Analysis Standards] 1 Simultaneous analysis of mycotoxins by liquid chromatography/ tandem mass spectrometry [Feed Analysis Standards, Chapter 5, Section 1 9.1 ]
More informationSUPPLEMENTARY DATA. Materials and Methods
SUPPLEMENTARY DATA Materials and Methods HPLC-UV of phospholipid classes and HETE isomer determination. Fractionation of platelet lipid classes was undertaken on a Spherisorb S5W 150 x 4.6 mm column (Waters
More informationIdentification of a xylose-containing cerebroside in the salt gland of the herring gull
dentification of a xylose-containing cerebroside in the salt gland of the herring gull Karl-Anders Karlsson, Bo E. Samuelsson, and Goran 0. Steen Department of Medical Biochemistry, University of Goteborg,
More informationGlycosyl composition of polysaccharide from Tinospora cordifolia. II. Glycosyl linkages
Acta Pharm. 54 (2004) 73 78 Short communication Glycosyl composition of polysaccharide from Tinospora cordifolia. II. Glycosyl linkages MUSLIARAKATBACKER JAFAR 1* P. AZADI 2 1 Department of Chemistry,
More informationSupporting Information. Copyright Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, 2007
Supporting Information Copyright Wiley-VCH Verlag GmbH & Co. KGaA, 695 Weinheim, 7 Copyright Wiley-VCH Verlag GmbH & Co. KGaA, 695 Weinheim, 7 Supporting Information for SorF, A Glycosyltransferase with
More informationComparison of Full Scan MS2 and MS3 Linear Ion Trap Approaches for Quantitation of Vitamin D
Comparison of Full Scan MS2 and MS3 Linear Ion Trap Approaches for Quantitation of Vitamin D Julie A. Horner 1, Marta Kozak 1, Subodh Nimkar 1, and August A. Specht 1 1 Thermo Fisher Scientific, San Jose,
More informationMass-Spectrometric Analysis of Lipids (Lipidomics)
Mass-Spectrometric Analysis of Lipids (Lipidomics) 1. Identification 2. Quantification 3. Metabolism Why to do lipidomics? Biology: Functions of different lipids? Medicine: Diagnostics and Therapy Industry:
More informationEssential Lipidomics Experiments using the LTQ Orbitrap Hybrid Mass Spectrometer
Application Note: 367 Essential Lipidomics Experiments using the LTQ rbitrap Hybrid Mass Spectrometer Thomas Moehring 1, Michaela Scigelova 2, Christer S. Ejsing 3, Dominik Schwudke 3, Andrej Shevchenko
More informationMass Spectrometry based metabolomics
Mass Spectrometry based metabolomics Metabolomics- A realm of small molecules (
More informationTitle Spot Test Method Convenient in Column Chromatography for Det Author(s) Morita, Shigeru; Hanai, Tetsuya Citation Bulletin of the Institute for Chemi University (1975), 53(3): 279-283 Issue Date 1975-09-16
More informationSupporting information
Supporting information A novel lipidomics workflow for improved human plasma identification and quantification using RPLC-MSn methods and isotope dilution strategies Evelyn Rampler 1,2,3, Angela Criscuolo
More informationRapid and Sensitive Screening of Benzodiazepines in Serum Using Liquid Chromatography-APCI-Linear Ion Trap System
T2007 Seattle, Washington Rapid and Sensitive Screening of Benzodiazepines in Serum Using Liquid hromatography-api-linear Ion Trap System Viktor Vorisek *, Vilma Habrdova, Pavel Zivny and Vladimir Palicka
More informationHerlyn Lab - Monoclonal Antibodies
Herlyn Lab - Monoclonal Antibodies GI Tract tumors I. Lewis and related antigens 1. 1116-NS-19-9 (CO 19-9), IgG1, Sialylated Le a Koprowski et al. 1979 2. 129-2-C3-9-11 (CO 29.11), IgG1, Sialylated Le
More informationAdvantages of Ion Mobility Q-TOF for Characterization of Diverse Biological Molecules
Advantages of Ion Mobility Q-TOF for Characterization of Diverse Biological Molecules Add a New Dimension to your Research Capability with Agilent s New Drift Ion Mobility Q-TOF System Overview: 6560 IM
More informationAnalysis of HMF by HPLC
COST Action 927 Training School Building Skills on the Analysis of Thermal Process Contaminants in Foods 22-26 October 2007, Ankara Analysis of HMF by HPLC Vural Gökmen O O OH Background O COOH O R 2 Carbonyl
More informationGlycolipid stage-specific embryonic antigens (SSEA-I) in kidneys of male and female C57BL/6J and beige adult mice
Glycolipid stage-specific embryonic antigens (SSEA-) in kidneys of male and female C57BL/6J and beige adult mice Marcia A. Williams, Sonja K. Gross, James E. Evans, and Robert H. McCluer Department of
More informationO O H. Robert S. Plumb and Paul D. Rainville Waters Corporation, Milford, MA, U.S. INTRODUCTION EXPERIMENTAL. LC /MS conditions
Simplifying Qual/Quan Analysis in Discovery DMPK using UPLC and Xevo TQ MS Robert S. Plumb and Paul D. Rainville Waters Corporation, Milford, MA, U.S. INTRODUCTION The determination of the drug metabolism
More informationSupplementary Information
Supplementary Information Molecular imaging of brain localization of liposomes in mice using MALDI mass spectrometry Annabelle Fülöp 1,2, Denis A. Sammour 1,2, Katrin Erich 1,2, Johanna von Gerichten 4,
More informationOrganic Chemistry Laboratory Fall Lecture 3 Gas Chromatography and Mass Spectrometry June
344 Organic Chemistry Laboratory Fall 2013 Lecture 3 Gas Chromatography and Mass Spectrometry June 19 2013 Chromatography Chromatography separation of a mixture into individual components Paper, Column,
More informationMALDI Imaging Drug Imaging Detlev Suckau Head of R&D MALDI Bruker Daltonik GmbH. December 19,
MALDI Imaging Drug Imaging Detlev Suckau Head of R&D MALDI Bruker Daltonik GmbH December 19, 2014 1 The principle of MALDI imaging Spatially resolved mass spectra are recorded Each mass signal represents
More informationSupporting Information
Supporting Information Development of a High Coverage Pseudotargeted Lipidomics Method Based on Ultra-High Performance Liquid Chromatography-Mass Spectrometry Qiuhui Xuan 1,2#, Chunxiu Hu 1#, Di Yu 1,2,
More informationTime (min) Supplementary Figure 1: Gas decomposition products of irradiated DMC.
200000 C 2 CH 3 CH 3 DMC 180000 160000 140000 Intensity 120000 100000 80000 60000 40000 C 2 H 6 CH 3 CH 2 CH 3 CH 3 CCH 3 EMC DEC 20000 C 3 H 8 HCCH 3 5 10 15 20 25 Time (min) Supplementary Figure 1: Gas
More informationMinutes Figure S1. HPLC separation of nucleosides from LC/ESI-MS analysis of a total enzymatic Trp
100 A % Relative Abundance m m Ø acp 5 m Øm 5 m m 7 m s * 6 ia m * 0 5 10 15 0 5 0 5 40 Minutes Figure S1. HPL separation of nucleosides from L/ESI-MS analysis of a total enzymatic digest of mt trna. V
More informationConsequently, lipoprotein fractions have been analyzed
THE PHOSPHOLIPID COMPOSITION OF HUMAN SERUM LIPOPROTEIN FRACTIONS SEPARATED BY ULTRACENTRIFUGATION * BY GERALD B. PHILLIPS (From the Departments of Biochemistry and Medicine, College of Physicians and
More informationNovel Fucolipids of Human Adenocarcinoma: Characterization of the Major LeY Antigen of Human Adenocarcinoma as Trifucosylnonaosyl
THE JOURNAL OF BOLOGCAL CHEMSTRY 0 1986 by The American Society of Biological Chemists, nc Vol. 261, No. 24, ssue of August 25, PP. 11247-11253,1386 Printed in U. SA. Novel Fucolipids of Human Adenocarcinoma:
More informationDry eye disease commonly known as atopic keratoconjunctivitis is an autoimmune disease of
4.1. Introduction Dry eye disease commonly known as atopic keratoconjunctivitis is an autoimmune disease of eyes. The disease is characterized by lesser or some time no-significant production of tear;
More informationCharacterization of Disulfide Linkages in Proteins by 193 nm Ultraviolet Photodissociation (UVPD) Mass Spectrometry. Supporting Information
Characterization of Disulfide Linkages in Proteins by 193 nm Ultraviolet Photodissociation (UVPD) Mass Spectrometry M. Montana Quick, Christopher M. Crittenden, Jake A. Rosenberg, and Jennifer S. Brodbelt
More informationIon fragmentation of small molecules in mass spectrometry
Ion fragmentation of small molecules in mass spectrometry Jeevan Prasain jprasain@uab.edu 6-2612 Nomenclature: the main names and acronyms used in mass spectrometry Molecular ion: Ion formed by addition
More informationFlow-Through Electron Capture Dissociation in a novel Branched RF Ion Trap
Flow-Through Electron Capture Dissociation in a novel Branched RF Ion Trap Takashi Baba, J. Larry Campbell, Yves Le Blanc, Jim. W. Hager and Bruce A. Thomson ASMS, June 18 / 2014 1 2014 AB SCIEX Trapping
More informationMass Spectrometry Introduction
Mass Spectrometry Introduction Chem 744 Spring 2013 What MS is and is not MS is NOT a spectroscopic method. Molecules are not absorbing EM radiation MS is the generation, separation and characterization
More informationCALF HEART LECTIN REACTS WITH BLOOD GROUP Ii ANTIGENS AND OTHER PRECURSOR CHAINS OF THE MAJOR BLOOD GROUP ANTIGENS
Volume 99, number 1 FEBS LETTERS March 1979 CALF HEART LECTIN REACTS WITH BLOOD GROUP Ii ANTIGENS AND OTHER PRECURSOR CHAINS OF THE MAJOR BLOOD GROUP ANTIGENS Robert A. CHILDS and Ten FEIZI Division of
More informationAutomated Sample Preparation for Profiling Fatty Acids in Blood and Plasma using the Agilent 7693 ALS
Automated Sample Preparation for Profiling Fatty Acids in Blood and Plasma using the Agilent 7693 ALS Application Note Clinical Research Authors Frank David and Bart Tienpont, Research Institute for Chromatography,
More informationDesigner Cannabinoids
Liquid Chromatography Mass Spectrometry SSI-LCMS-010 Designer Cannabinoids LCMS-8030 Summary A rapid LC-MS-MS method for determination of designer cannabinoids in smokeable herbs was developed. Background
More informationSteviol Glycosides from Stevia rebaudiana Bertoni
0 out of 21 Residue Monograph prepared by the meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA), 84th meeting 2017 Steviol Glycosides from Stevia rebaudiana Bertoni This monograph
More informationTECHNICAL BULLETIN. R 2 GlcNAcβ1 4GlcNAcβ1 Asn
GlycoProfile II Enzymatic In-Solution N-Deglycosylation Kit Product Code PP0201 Storage Temperature 2 8 C TECHNICAL BULLETIN Product Description Glycosylation is one of the most common posttranslational
More informationNew Solvent Grade Targeted for Trace Analysis by UHPLC-MS
New Solvent Grade Targeted for Trace Analysis by UHPLC-MS Subhra Bhattacharya, Deva H. Puranam, and Stephen C. Roemer Thermo Fisher Scientific Fisher Chemical, One Reagent Lane, Fair Lawn, NJ Material
More informationUltra Performance Liquid Chromatography Coupled to Orthogonal Quadrupole TOF MS(MS) for Metabolite Identification
22 SEPARATION SCIENCE REDEFINED MAY 2005 Ultra Performance Liquid Chromatography Coupled to Orthogonal Quadrupole TOF MS(MS) for Metabolite Identification In the drug discovery process the detection and
More informationPrinciples of Shotgun Lipidomics
Principles of Shotgun Lipidomics Xianlin Han Diabetes and Obesity Research Center Sanford-Burnham Medical Research Institute Lake Nona Orlando, FL 32827 What is shotgun lipidomics? Original definition
More informationStructures of the Oligosaccharide Chains in Swine Trachea Mucin Glycoproteins*
THE JOURNAL OF BOLOGCAL CHEMSTRY 0 1984 by The American Society of Biological Chemists, nc Vol. 259, No. ssue Structures of the Oligosaccharide Chains in Swine Trachea Mucin Glycoproteins* (Received for
More informationThermo Scientific LipidSearch Software for Lipidomics Workflows. Automated Identification and Relative. Quantitation of Lipids by LC/MS
Thermo Scientific LipidSearch Software for Lipidomics Workflows Automated Identification and Relative of Lipids by LC/MS The promise of lipidomics Lipidomics is a new field of study crucial for understanding
More informationLC-MS Analysis of Botanicals
Botanical workshop UAB, Sept 11, 26 LC-MS Analysis of Botanicals Jeevan K. Prasain, Ph.D. Department of Pharmacology & Toxicology, UAB Purdue-UAB Botanicals Center for Age-related Disease Applications
More informationBiomolecular Mass Spectrometry
Lipids ot different than other organic small molecules Carbohydrates Polymers of monosaccharides linked via glycosidic bonds (acetals/ ketals) many different combinationsvery interesting no time ucleic
More informationSUPPLEMENTARY MATERIAL
SUPPLEMENTARY MATERIAL Artepillin C, is it a good marker for quality control of Brazilian Green Propolis? Cui-ping Zhang 1, Xiao-ge Shen 1, Jia-wei Chen 1, Xia-sen Jiang 1, Kai Wang 2, Fu-liang Hu 1 *
More informationBIOCHEMICAL DIAGNOSIS OF DISEASES CAUSING OLIGOSACCHARIDURIA BY MASS SPECTROMETRY
BIOCHEMICAL DIAGNOSIS OF DISEASES CAUSING OLIGOSACCHARIDURIA BY MASS SPECTROMETRY Pedro Ruiz-Sala, Isaac Ferrer-López Centro de Diagnóstico de Enfermedades Moleculares CEDEM, Universidad Autónoma de Madrid,
More informationEdgar Naegele. Abstract
Simultaneous determination of metabolic stability and identification of buspirone metabolites using multiple column fast LC/TOF mass spectrometry Application ote Edgar aegele Abstract A recent trend in
More informationHakon Leffler, Gunnar C. Hansson, and Nicklas Stromberg
THE JOURNAL OF BOLOGCAL CHEMSTRY 0 1986 by The American Society of Biological Chemists, nc Vol. 261, No. 3, ssue of January pp. 14401444, 1986 Printed in U.S.A. A Novel Sulfoglycosphingolipid of Mouse
More informationGas Chromatography/ Mass Spectrometry
Gas Chromatography/ Mass Spectrometry Edited by H.F. Linskens and J.F. Jackson Contributors R.S. Bandurski G. Combaut A.Ehmann P.Hedden B.Janistyn H.Kameoka H.Kodama D.V.Lynch J.K.MacLeod H.Nyberg L.M.S.Palni
More informationApplication Note # FTMS-46 solarix XR: Analysis of Complex Mixtures
Application Note # FTMS-46 solarix XR: Analysis of Complex Mixtures Introduction Natural organic matter (NOM) as well as crude oil and crude oil fractions are very complex mixtures of organic compounds
More informationDetermination of red blood cell fatty acid profiles in clinical research
Application Note Clinical Research Determination of red blood cell fatty acid profiles in clinical research Chemical ionization gas chromatography tandem mass spectrometry Authors Yvonne Schober 1, Hans
More informationresting and tetragastrin stimulated gastric juice of patients with non-neoplastic diseases of the stomach
J Clin Pathol 1985;38:320-326 Blood group antigens A, B, H, Lea, Leb, and I(Ma) in resting and tetragastrin stimulated gastric juice of patients with non-neoplastic diseases of the stomach JEAN K PICARD,*
More informationProfiling Flavonoid Isomers in Highly Complex Citrus Juice Samples Using UPLC Ion Mobility Time-of-Flight Mass Spectrometry
Profiling Flavonoid Isomers in Highly Complex Citrus Juice Samples Using UPLC Ion Mobility Time-of-Flight Mass Spectrometry Michael McCullagh, 1 Kieran Neeson, 2 and Antonietta Gledhill 1 Waters Corporation,
More informationAvailable online Research Article
Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research, 2015, 7(12):519-523 Research Article ISSN : 0975-7384 CDEN(USA) : JCPRC5 Characterization of cyanidin 3-(6-acetylglucoside)-5-(3
More informationGlycosylation analysis of blood plasma proteins
Glycosylation analysis of blood plasma proteins Thesis booklet Eszter Tóth Doctoral School of Pharmaceutical Sciences Semmelweis University Supervisor: Károly Vékey DSc Official reviewers: Borbála Dalmadiné
More informationImproved method for the quantification of lysophospholipids including enol ether
Supplemental Material Improved method for the quantification of lysophospholipids including enol ether species by liquid chromatography-tandem mass spectrometry James G. Bollinger *, Hiromi Ii*, Martin
More informationAnalysis of FAMEs Using Cold EI GC/MS for Enhanced Molecular Ion Selectivity
APPLICATION NOTE Gas Chromatography/ Mass Spectrometry Author: Adam Patkin PerkinElmer, Inc. Shelton, CT Analysis of FAMEs Using GC/MS for Enhanced Molecular Ion Selectivity Introduction Characterization
More informationRelative Quantitation of Human Polymorphonuclear Leukocyte Cell Membrane GPEtn Lipids
Relative Quantitation of Human Polymorphonuclear Leukocyte Cell Membrane GPEtn Lipids Using the QTRAP System with mtraq Reagents Karin A. Zemski-Berry 1, John M. Hevko 2, and Robert C. Murphy 1 1 Department
More informationHelicobacter pylori and Complex Gangliosides
INFECTION AND IMMUNITY, Mar. 2004, p. 1519 1529 Vol. 72, No. 3 0019-9567/04/$08.00 0 DOI: 10.1128/IAI.72.3.1519 1529.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved. Helicobacter
More informationSmall Scale Preparative Isolation of Corticosteroid Degradation Products Using Mass-Based Fraction Collection Application
Small Scale Preparative Isolation of Corticosteroid Degradation Products Using Mass-Based Fraction Collection Application Pharmaceutical Author Cliff Woodward Agilent Technologies, Inc. 285 Centerville
More informationPhosphorylated glycosphingolipids essential for cholesterol mobilization in C. elegans
SUPPLEMENTARY INFORMATION Phosphorylated glycosphingolipids essential for cholesterol mobilization in C. elegans Sebastian Boland, Ulrike Schmidt, Vyacheslav Zagoriy, Julio L. Sampaio, Raphael Fritsche,
More informationJose Castro-Perez, Henry Shion, Kate Yu, John Shockcor, Emma Marsden-Edwards, Jeff Goshawk Waters Corporation, Milford, MA, U.S. and Manchester, UK
HIGH-THRUGHPUT REACTIVE METABLITE SCREEIG FR DICLFEAC BY UPLC AD XEV TQ MS WITH SCAWAVE Jose Castro-Perez, Henry Shion, Kate Yu, John Shockcor, Emma Marsden-Edwards, Jeff Goshawk Waters Corporation, Milford,
More informationLC-Based Lipidomics Analysis on QTRAP Instruments
LC-Based Lipidomics Analysis on QTRAP Instruments Junhua Wang and Paul RS Baker SCIEX LC-Based Lipidomics Analysis Topics Covered Lipid extraction techniques Hydrophilic Interaction Chromatography (HILIC)
More informationThe addition of sugar moiety determines the blood group
The addition of sugar moiety determines the blood group Sugars attached to glycoproteins and glycolipids on the surfaces of red blood cells determine the blood group termed A, B, and O. The A and B antigens
More informationAnalytical Method for 2, 4, 5-T (Targeted to Agricultural, Animal and Fishery Products)
Analytical Method for 2, 4, 5-T (Targeted to Agricultural, Animal and Fishery Products) The target compound to be determined is 2, 4, 5-T. 1. Instrument Liquid Chromatograph-tandem mass spectrometer (LC-MS/MS)
More informationMetabolism of echitamine and plumbagin in rats
J. Biosci., Vol. 3, Number 4, December 1981, pp. 395-400. Printed in India. Metabolism of echitamine and plumbagin in rats B. CHANDRASEKARAN and B. NAGARAJAN Microbiology Division, Cancer Institute, Madras
More informationApplicationNOTE EXACT MASS MEASUREMENT OF ACTIVE COMPONENTS OF TRADITIONAL HERBAL MEDICINES BY ORTHOGONAL ACCELERATION TIME-OF-FLIGHT.
Objective The aim of the study presented is to determine the presence of target Gingkolides in Gingko biloba leaf extract. The data presented shows Gingkolides determined to be present in the extract analyzed.
More informationIdentification of Aromatic Fatty Acid Ethyl Esters
Chapter 3.2 Identification of Aromatic Fatty Acid Ethyl Esters The only use of gas chromatography is not sufficient to determine which compounds are eluting from the catalytic bed. At the beginning of
More informationIdentification of Steroids in Water by Ion Trap LC/MS/MS Application
Identification of Steroids in Water by Ion Trap LC/MS/MS Application Environmental Author Paul Zavitsanos and Christine Miller Agilent Technologies, Inc. Centerville Road Wilmington, DE 9- USA Abstract
More informationMS/MS as an LC Detector for the Screening of Drugs and Their Metabolites in Race Horse Urine
Application Note: 346 MS/MS as an LC Detector for the Screening of Drugs and Their Metabolites in Race Horse Urine Gargi Choudhary and Diane Cho, Thermo Fisher Scientific, San Jose, CA Wayne Skinner and
More informationChapter 1. Chemistry of Life - Advanced TABLE 1.2: title
Condensation and Hydrolysis Condensation reactions are the chemical processes by which large organic compounds are synthesized from their monomeric units. Hydrolysis reactions are the reverse process.
More informationA STUDY OF THE CONCENTRATION AND PROPERTIES OF TWO AMYLASES OF BARLEY MALT
A STUDY OF THE CONCENTRATION AND PROPERTIES OF TWO AMYLASES OF BARLEY MALT BY M. L. CALDWELL AND S. E. DOEBBELING (From the Department of Chemistry, Columbia University, New York) (Received for publication,
More information